HALO — Halozyme Therapeutics Inc. price, chart and key statistics
Technical analysis2
Overlay lines0
Addendum charts0
Key stats#
Data provided bySource: Twelve DataPrice data
- Price
- $95.97
- YTD price return
- +42.60%
- YTD total return
- +42.60%
- Market cap
- 10.9B
- Enterprise value
- 13.2B
- Shares outstanding
- 114M
- 52W low
- $61.23
- 52W high
- $134.00
- From 52W high
- -28.38%
- From 52W low
- +56.74%
- 52W range
- 48%$61.23–$134
- Beta
- 0.85
Volume
- Rel volume
- 0.88×
- 30D volume
- 2.3M
- 30D $ vol
- 268.3M
Insider trading
- Insider net 1W
- −$6.0M
- Insider net 1M
- −$6.0M
- Insider net 3M
- −$21.7M
- Insider net 1Y
- −$48.6M
Form 4 transactions by trade date, as filed; latest on file 2026-11-16.
Fundamentals
- Sales (ttm)
- 1.8B
- Sales/share
- $15.81
- EPS (ttm)
- $3.97
- FCF (ttm)
- 885.9M
- FCF/share
- $7.77
- Book value/share
- -$0.48
- Net margin
- 26.93%
- ROA
- 13.98%
- Current ratio
- 3.88
Growth (CAGR, ttm) · 10Y
- Sales
- +45.06%+32.16%+31.24%+27.41%
- Net income
- -18.50%+24.11%+3.48%n/a
- FCF
- +47.10%+35.80%+27.32%n/a
- Shares
- -3.05%-4.79%-4.13%-1.27%
Per-share growth (CAGR, ttm) · 10Y
- EPS
- -16.28%+28.67%+7.32%n/a
- Sales/share
- +49.63%+38.81%+36.90%+29.05%
- FCF/share
- +51.73%+42.63%+32.81%n/a
- Price
- +36.04%+33.94%+21.12%+22.14%
- Total return
- +36.04%+33.94%+21.12%+22.14%
Fundamentals end at the last reported quarter; price and total return end at the latest close.
Valuation
- P/E (ttm)
- 24.2×
- P/OI (ttm)
- 16.2×
- Fwd P/E
- 9.1×
- P/S (ttm)
- 6.1×
- P/B (mrq)
- -198.1×
- P/FCF (ttm)
- 12.4×
- EV/EBITDA (fy)
- 16.4×
- EV/Sales (ttm)
- 7.3×
- FCF yield (ttm)
- 8.10%
- Buyback yield (realized, 1y)
- 3.05%
- Shareholder yield (realized, 1y)
- 3.05%
- Buyback yield (cash, ttm)
- 3.66%
- Shareholder yield (cash, ttm)
- 3.66%
Vs own 10Y history
- P/E
- 48th
- P/OI
- 32nd
- P/S
- 11th
- P/B
- 95th
- P/FCF
- 10th
Bar = where today’s multiple sits in HALO’s own 10-year range:near a decade-low (cheap)→mid-range→near a decade-high (rich).
Performance · price returntotal return · as of 2026-11-17#
Data provided bySource: Twelve DataFundamentals#
Operating income
5Y CAGR +26.6%10Y n/mYoY +35.4%EPS (diluted)
5Y CAGR +23.0%10Y n/mYoY +40.6%Free cash flow
5Y CAGR +64.8%10Y n/mYoY +45.4%TTM: operating cash flow $898.3M, capex −$12.4M
Q3 2026: operating cash flow $258.3M, capex −$3M
Shares (diluted)
5Y −12.4%10Y −2.2%YoY +0.2%Net income
5Y CAGR +19.7%10Y n/mYoY +41.0%About Halozyme Therapeutics#
Data provided bySource: Twelve DataHalozyme Therapeutics Inc. is a biopharmaceutical technology company focused on drug delivery solutions and specialty medicines. Its core platform, ENHANZE, uses the proprietary enzyme rHuPH20 to help enable subcutaneous delivery of injectable therapies and fluids, supporting more convenient administration and improved patient comfort. The company also develops, manufactures, and commercializes drug-device combination products with advanced auto-injector technology for use in areas such as oncology and other specialty therapeutic settings. In addition to its platform business, Halozyme Therapeutics Inc. markets proprietary products including Hylenex and XYOSTED, and works with pharmaceutical partners to support a range of commercial and development-stage programs. Headquartered in San Diego, California, Halozyme Therapeutics Inc. plays a specialized role in the biopharmaceutical market by providing technologies that help improve how existing medicines are delivered and used.
San Diego, CA·423 employees·Biotechnology·halozyme.com·As of Oct 28, 2026
Recent filings#
- Nov 5Earnings · Earnings release — EPS $2.27 vs $2.17 est. (+4.6%); revenue $493.0M (+39% y/y) 15.7%
- Sep 188-K · Halozyme Therapeutics, Inc. Announces Pricing of Upsized Private Offering of $1.3 Billion of Convertible Senior Notes due 2033
- Sep 168-K · Halozyme Therapeutics, Inc. Announces Proposed Offering of $1.05 Billion of Convertible Senior Notes due 2033
- Aug 6Earnings · Earnings release — EPS $2.17 vs $1.73 est. (+25.4%); revenue $481.0M (+48% y/y) 20.2%
ETFs holding HALO#
21 of the 193 ETFs ChartRow carries live hold HALO. The 8 largest positions, by the weight each fund filed in its latest SEC N-PORT report (Jun 26 to Aug 26).
| Fund | Name | Filed weight |
|---|---|---|
| XBI | SPDR S&P Biotech ETF | 1.0% |
| IBB | iShares Biotechnology ETF | 0.7% |
| VBK | Vanguard Small-Cap Growth ETF | 0.3% |
| IJH | iShares Core S&P Mid-Cap ETF | 0.3% |
| MDY | SPDR S&P MidCap 400 ETF Trust | 0.3% |
| IWP | iShares Russell Mid-Cap Growth ETF | 0.3% |
| VHT | Vanguard Health Care ETF | 0.2% |
| VB | Vanguard Small-Cap ETF | 0.1% |
Related Healthcare#
Data provided bySource: Twelve Data| Ticker | Name | 1M | 1D |
|---|---|---|---|
| LLY | Eli Lilly and Company | +12.61% | -1.13% |
| JNJ | Johnson & Johnson | +9.05% | -1.36% |
| ABBV | AbbVie Inc. | +2.59% | -0.59% |
| MRK | Merck & Co. Inc. | -1.77% | -0.75% |
| UNH | UnitedHealth Group Incorporated Common Stock (DE) | -2.93% | -5.42% |
| NVS | Novartis AG | +5.65% | -0.67% |
| TMO | Thermo Fisher Scientific Inc. | -0.47% | -0.66% |
| AMGN | Amgen Inc. | +5.88% | -0.95% |
